BeOne Medicines Reports Improved Survival in Phase 3 Cancer Study
The company said a combination treatment improved overall survival among patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
By Elias SchisgallBeOne Medicines said a new combined treatment for esophageal cancer demonstrated an improved overall survival rate in a Phase 3 study.The oncology company said patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma who took a combination of Tevi…